Semin Respir Crit Care Med 2019; 40(03): 323-339
DOI: 10.1055/s-0039-1698285
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Management of Malignant Pleural Effusions—What Is New

Rajesh Thomas
1   Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia
2   Centre for Respiratory Health, School of Medicine, University of Western Australia, Perth, Australia
,
Bapti Roy
3   Department of Respiratory and Sleep Medicine, Westmead Hospital, Sydney, Australia
,
Fabien Maldonado
4   Department of Medicine, Vanderbilt University, Nashville, Tennessee
,
Y.C. Gary Lee
1   Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia
2   Centre for Respiratory Health, School of Medicine, University of Western Australia, Perth, Australia
5   Department of Medicine, University of Hong Kong, Hong Kong
› Author Affiliations
Funding R.T. has research fellowship funding support from the National Health and Medical Research Council and Cancer Council Western Australia and has received project funding from Sir Charles Gairdner Research Advisory Group. Y.C.G.L. is an Australian Medical Research Future Fund Practitioner Fellow and has received project funding from the National Health Medical Research Council, Cancer Australia, Cancer Council Western Australia, Sir Charles Gairdner Research Advisory Group, and the Dust Diseases Authority.
Further Information

Publication History

Publication Date:
16 September 2019 (online)

Abstract

Malignant pleural effusion (MPE) is a common and challenging problem. Patients affected by MPE have a poor prognosis and suffer from breathlessness and impaired quality of life. The management of MPE has barely changed for many decades; however, recent research has driven new paradigms in the diagnosis and treatment of MPE and stimulated novel concepts that are being evaluated in many ongoing studies. This review provides an overview of recent advances in the diagnosis of MPE, including new cytopathology and imaging techniques, and the landmark studies that provide a solid evidence base to support the use of indwelling pleural catheters as first-line treatment in MPE. Lingering management dilemmas, including optimal chest drainage tube and role of surgery in MPE, and key knowledge gaps that are the focus of ongoing research are also highlighted.

Contributions

Guarantor: R.T. and Y.C.G.L.; Manuscript writing and final approval: all authors.


 
  • References

  • 1 American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162 (05) 1987-2001
  • 2 Marel M, Zrůstová M, Stasný B, Light RW. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest 1993; 104 (05) 1486-1489
  • 3 van Zandwijk N, Clarke C, Henderson D. , et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis 2013; 5 (06) E254-E307
  • 4 Rodrîguez-Panadero F, Borderas Naranjo F, López Mejîas J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J 1989; 2 (04) 366-369
  • 5 Clive AO, Kahan BC, Hooper CE. , et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014; 69 (12) 1098-1104
  • 6 Fysh ETH, Bielsa S, Budgeon CA. , et al. Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion. Chest 2015; 147 (06) 1629-1634
  • 7 Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest 2000; 117 (01) 87-95
  • 8 Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015; 20 (04) 654-659
  • 9 Lee YC, Light RW. Pleural effusion: overview. In: Laurent G, Shapiro S. , eds. Encyclopedia of Respiratory Diseases. 4th ed. Oxford: Elsevier; 2006: 353-358
  • 10 Marel M, Stastny B, Melínová L, Svandová E, Light RW. Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest 1995; 107 (06) 1598-1603
  • 11 National Patient Safety Agency. Rapid Response Report NPSA/2008/RRR003: Risks of Chest Drain Insertion. London: NPSA; 2008
  • 12 Fortin M, Taghizadeh N, Tremblay A. Procedures performed during hospitalizations for malignant pleural effusions: data from the 2012 National Inpatient Sample. Respiration 2018; 95 (04) 228-234
  • 13 Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 2010; 65 (Suppl. 02) ii32-ii40
  • 14 Bibby AC, Dorn P, Psallidas I. , et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg 2019; 55 (01) 116-132
  • 15 Feller-Kopman DJ, Reddy CB, DeCamp MM. , et al. Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med 2018; 198 (07) 839-849
  • 16 Thomas R, Francis R, Davies HE, Lee YC. Interventional therapies for malignant pleural effusions: the present and the future. Respirology 2014; 19 (06) 809-822
  • 17 Fysh ETH, Thomas R, Tobin C, Kuok YJ, Lee YCG. Air in the pleural cavity enhances detection of pleural abnormalities by CT scan. Chest 2018; 153 (06) e123-e128
  • 18 Hjerpe A, Ascoli V, Bedrossian C. , et al. Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Cytojournal 2015; 12: 26
  • 19 Segal A, Sterrett GF, Frost FA. , et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 2013; 45 (01) 44-48
  • 20 Sidhu C, Louw A, Brims F, Creaney J. Malignant pleural mesothelioma: an update for pulmonologists. Curr Opin Pulm Med 2019; 8 (02) 40-49
  • 21 Alakus H, Yost SE, Woo B. , et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med 2015; 13: 122
  • 22 Bott M, Brevet M, Taylor BS. , et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43 (07) 668-672
  • 23 Guo G, Chmielecki J, Goparaju C. , et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015; 75 (02) 264-269
  • 24 Nasu M, Emi M, Pastorino S. , et al. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 2015; 10 (04) 565-576
  • 25 Yoshikawa Y, Sato A, Tsujimura T. , et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012; 103 (05) 868-874
  • 26 Zauderer MG, Bott M, McMillan R. , et al. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol 2013; 8 (11) 1430-1433
  • 27 Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax 2009; 64 (02) 139-143
  • 28 Salamonsen M, Ware R, Fielding D. A new method for performing continuous manometry during pleural effusion drainage. Respiration 2014; 88 (01) 61-66
  • 29 Raj V, Kirke R, Bankart MJ, Entwisle JJ. Multidetector CT imaging of pleura: comparison of two contrast infusion protocols. Br J Radiol 2011; 84 (1005): 796-799
  • 30 Leung AN, Müller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 1990; 154 (03) 487-492
  • 31 Porcel JM, Pardina M, Bielsa S, González A, Light RW. Derivation and validation of a CT scan scoring system for discriminating malignant from benign pleural effusions. Chest 2015; 147 (02) 513-519
  • 32 Corcoran JP, Acton L, Ahmed A. , et al. Diagnostic value of radiological imaging pre- and post-drainage of pleural effusions. Respirology 2016; 21 (02) 392-395
  • 33 Porcel JM, Hernández P, Martínez-Alonso M, Bielsa S, Salud A. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest 2015; 147 (02) 502-512
  • 34 Coolen J, De Keyzer F, Nafteux P. , et al. Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience. Radiology 2012; 263 (03) 884-892
  • 35 Pena E, Ojiaku M, Inacio JR. , et al. Can CT and MR shape and textural features differentiate benign versus malignant pleural lesions?. Acad Radiol 2017; 24 (10) 1277-1287
  • 36 Rahman NM, Gleeson FV. Image-guided pleural biopsy. Curr Opin Pulm Med 2008; 14 (04) 331-336
  • 37 de Fonseka D, Underwood W, Stadon L. , et al. Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial). BMJ Open Respir Res 2018; 5 (01) e000270
  • 38 Bintcliffe OJ, Hallifax RJ, Edey A. , et al. Spontaneous pneumothorax: time to rethink management?. Lancet Respir Med 2015; 3 (07) 578-588
  • 39 Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med 1991; 114 (04) 271-276
  • 40 Hucker J, Bhatnagar NK, al-Jilaihawi AN, Forrester-Wood CP. Thoracoscopy in the diagnosis and management of recurrent pleural effusions. Ann Thorac Surg 1991; 52 (05) 1145-1147
  • 41 DePew ZS, Verma A, Wigle D, Mullon JJ, Nichols FC, Maldonado F. Nonspecific pleuritis: optimal duration of follow-up. Ann Thorac Surg 2014; 97 (06) 1867-1871
  • 42 Dhooria S, Singh N, Aggarwal AN, Gupta D, Agarwal R. A randomized trial comparing the diagnostic yield of rigid and semirigid thoracoscopy in undiagnosed pleural effusions. Respir Care 2014; 59 (05) 756-764
  • 43 Thomas R, Karunarathne S, Jennings B. , et al. Pleuroscopic cryoprobe biopsies of the pleura: a feasibility and safety study. Respirology 2015; 20 (02) 327-332
  • 44 Dhooria S, Bal A, Sehgal IS. , et al. Pleural cryobiopsy versus flexible forceps biopsy in subjects with undiagnosed exudative pleural effusions undergoing semirigid thoracoscopy: a crossover randomized trial (COFFEE Trial). Respiration 2019; 24: 1-9 doi:10-115a/000497212
  • 45 Lentz RJ, Lerner AD, Pannu JK. , et al. Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial. Lancet Respir Med 2019; 7 (05) 447-455
  • 46 Martin GA, Tsim S, Kidd AC. , et al. Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. BMJ Open Respir Res 2018; 5 (01) e000293
  • 47 West SD, Davies RJ, Lee YC. Pleurodesis for malignant pleural effusions: current controversies and variations in practices. Curr Opin Pulm Med 2004; 10 (04) 305-310
  • 48 Dresler CM, Olak J, Herndon II JE. , et al; Cooperative Groups Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cooperative Oncology Group; Radiation Therapy Oncology Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127 (03) 909-915
  • 49 Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J 2007; 30 (04) 759-762
  • 50 Davies HE, Mishra EK, Kahan BC. , et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307 (22) 2383-2389
  • 51 Thomas R, Fysh ETH, Smith NA. , et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA 2017; 318 (19) 1903-1912
  • 52 Muruganandan S, Azzopardi M, Fitzgerald DB. , et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med 2018; 6 (09) 671-680
  • 53 Putnam Jr JB, Light RW, Rodriguez RM. , et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999; 86 (10) 1992-1999
  • 54 Boshuizen RC, Vd Noort V, Burgers JA. , et al. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14). Lung Cancer 2017; 108: 9-14
  • 55 Efthymiou CA, Masudi T, Thorpe JA, Papagiannopoulos K. Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters. Interact Cardiovasc Thorac Surg 2009; 9 (06) 961-964
  • 56 Qureshi RA, Collinson SL, Powell RJ, Froeschle PO, Berrisford RG. Management of malignant pleural effusion associated with trapped lung syndrome. Asian Cardiovasc Thorac Ann 2008; 16 (02) 120-123
  • 57 Rahman NM, Pepperell J, Rehal S. , et al. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. JAMA 2015; 314 (24) 2641-2653
  • 58 Fysh ET, Tan SK, Read CA. , et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax 2013; 68 (06) 594-596
  • 59 Fysh ETH, Waterer GW, Kendall PA. , et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest 2012; 142 (02) 394-400
  • 60 Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006; 129 (02) 362-368
  • 61 Wahidi MM, Reddy C, Yarmus L. , et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial. Am J Respir Crit Care Med 2017; 195 (08) 1050-1057
  • 62 Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med 2011; 26 (01) 70-76
  • 63 Ost DE, Jimenez CA, Lei X. , et al. Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters. Chest 2014; 145 (06) 1347-1356
  • 64 Warren WH, Kalimi R, Khodadadian LM, Kim AW. Management of malignant pleural effusions using the Pleur(x) catheter. Ann Thorac Surg 2008; 85 (03) 1049-1055
  • 65 Lui MM, Thomas R, Lee YC. Complications of indwelling pleural catheter use and their management. BMJ Open Respir Res 2016; 3 (01) e000123
  • 66 Fysh ETH, Tremblay A, Feller-Kopman D. , et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. Chest 2013; 144 (05) 1597-1602
  • 67 Gilbert CR, Lee HJ, Akulian JA. , et al. A quality improvement intervention to reduce indwelling tunneled pleural catheter infection rates. Ann Am Thorac Soc 2015; 12 (06) 847-853
  • 68 Rahman NM, Maskell NA, West A. , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365 (06) 518-526
  • 69 Mekhaiel E, Kashyap R, Mullon JJ, Maldonado F. Infections associated with tunnelled indwelling pleural catheters in patients undergoing chemotherapy. J Bronchology Interv Pulmonol 2013; 20 (04) 299-303
  • 70 Morel A, Mishra E, Medley L. , et al. Chemotherapy should not be withheld from patients with an indwelling pleural catheter for malignant pleural effusion. Thorax 2011; 66 (05) 448-449
  • 71 Thomas R, Budgeon CA, Kuok YJ. , et al. Catheter tract metastasis associated with indwelling pleural catheters. Chest 2014; 146 (03) 557-562
  • 72 Tobin CL, Thomas R, Chai SM, Segal A, Lee YC. Histopathology of removed indwelling pleural catheters from patients with malignant pleural diseases. Respirology 2016; 21 (05) 939-942
  • 73 Thomas R, Piccolo F, Miller D. , et al. Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: a multicenter observational study. Chest 2015; 148 (03) 746-751
  • 74 Fysh ETH, Wrightson JM, Lee YCG, Rahman NM. Fractured indwelling pleural catheters. Chest 2012; 141 (04) 1090-1094
  • 75 Boshuizen RC, Onderwater S, Burgers SJ, van den Heuvel MM. The use of indwelling pleural catheters for the management of malignant pleural effusion--direct costs in a Dutch hospital. Respiration 2013; 86 (03) 224-228
  • 76 Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med 2010; 13 (01) 59-65
  • 77 Puri V, Pyrdeck TL, Crabtree TD. , et al. Treatment of malignant pleural effusion: a cost-effectiveness analysis. Ann Thorac Surg 2012; 94 (02) 374-379 , discussion 379–380
  • 78 Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest 2011; 139 (06) 1419-1423
  • 79 Penz ED, Mishra EK, Davies HE, Manns BJ, Miller RF, Rahman NM. Comparing cost of indwelling pleural catheter vs talc pleurodesis for malignant pleural effusion. Chest 2014; 146 (04) 991-1000
  • 80 Boujaoude Z, Bartter T, Abboud M, Pratter M, Abouzgheib W. Pleuroscopic pleurodesis combined with tunneled pleural catheter for management of malignant pleural effusion: a prospective observational study. J Bronchology Interv Pulmonol 2015; 22 (03) 237-243
  • 81 Ahmed L, Ip H, Rao D, Patel N, Noorzad F. Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway. Chest 2014; 146 (06) e190-e194
  • 82 Sivakumar P, Douiri A, West A. , et al. OPTIMUM: a protocol for a multicentre randomised controlled trial comparing out patient talc slurry via indwelling pleural catheter for malignant pleural effusion vs usual inpatient management. BMJ Open 2016; 6 (10) e012795
  • 83 Muruganandan S, Fitzgerald D, Stanley C, Read C, Thomas R, Lee YCG. Early pleurodesis via indwelling pleural catheter with talc for malignant effusions: the epitome study. Respirology 2017; 22: 239-240
  • 84 Tremblay A, Dumitriu S, Stather DR, Maceachern P, Illanes O, Kelly MM. Use of a drug eluting pleural catheter for pleurodesis. Exp Lung Res 2012; 38 (9–10): 475-482
  • 85 Bhatnagar R, Zahan-Evans N, Kearney C. , et al. A novel drug-eluting indwelling pleural catheter for the management of malignant effusions. Am J Respir Crit Care Med 2018; 197 (01) 136-138
  • 86 Fysh ET, Smith NA, Lee YC. Optimal chest drain size: the rise of the small-bore pleural catheter. Semin Respir Crit Care Med 2010; 31 (06) 760-768
  • 87 Parulekar W, Di Primio G, Matzinger F, Dennie C, Bociek G. Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions. Chest 2001; 120 (01) 19-25
  • 88 Clementsen P, Evald T, Grode G, Hansen M, Krag Jacobsen G, Faurschou P. Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study. Respir Med 1998; 92 (03) 593-596
  • 89 Parker LA, Charnock GC, Delany DJ. Small bore catheter drainage and sclerotherapy for malignant pleural effusions. Cancer 1989; 64 (06) 1218-1221
  • 90 Collop NA, Kim S, Sahn SA. Analysis of tube thoracostomy performed by pulmonologists at a teaching hospital. Chest 1997; 112 (03) 709-713
  • 91 Saydam O, Karapinar K, Gokce M. , et al. The palliative treatment with intrapleural streptokinase in patients with multiloculated malignant pleural effusion: a double-blind, placebo-controlled, randomized study. Med Oncol 2015; 32 (06) 612
  • 92 Okur E, Baysungur V, Tezel C, Ergene G, Okur HK, Halezeroglu S. Streptokinase for malignant pleural effusions: a randomized controlled study. Asian Cardiovasc Thorac Ann 2011; 19 (3–4): 238-243
  • 93 Mishra EK, Clive AO, Wills GH. , et al. Randomized controlled trial of urokinase versus placebo for nondraining malignant pleural effusion. Am J Respir Crit Care Med 2018; 197 (04) 502-508
  • 94 Sugarbaker DJ, Richards WG, Bueno R. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg 2014; 260 (04) 577-580 , discussion 580–582
  • 95 Rintoul RC, Ritchie AJ, Edwards JG. , et al; MesoVATS Collaborators. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 2014; 384 (9948): 1118-1127
  • 96 Thomas R, Jenkins S, Eastwood PR, Lee YC, Singh B. Physiology of breathlessness associated with pleural effusions. Curr Opin Pulm Med 2015; 21 (04) 338-345
  • 97 Thomas R, Azzopardi M, Muruganandan S. , et al. Protocol of the PLeural Effusion And Symptom Evaluation (PLEASE) study on the pathophysiology of breathlessness in patients with symptomatic pleural effusions. BMJ Open 2016; 6 (08) e013213